Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Inclusion Criteria

• •Age of 16 years and older
• •Receipt of entecavir or lamivudine in a previous entecavir study.
• •Participants who were, based on their response to entecavir:
• •Virologic nonresponders at Week 48
• •Partial virologic responders who became nonresponders during the second year of treatment
• •Partial virologic responders at Week 96
• •Complete responders who relapsed during postdosing follow-up
• •* Decompensated liver disease in AI463-048 that met 1 or more of the following criteria:
• •Nonresponse to adefovir after at least 24 weeks of treatment
• •Partial response to adefovir after 96 weeks of treatment
• •Complete response to adefovir after relapsing during postdosing follow-up
• •Demonstrated intolerance to adefovir
• •* Except for those participants enrolled from AI463-048, compensated liver disease.